Companies › Longboard Pharmaceuticals
1 active drug program in 2 registered trials: 2 Phase 3; Neurology; next expected readout Nov 2026.
Open in Phaseline: competitors, likelihood bands and readouts Company report
| Drug | Target | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|
| LP352 | – | Phase 3 | Developmental and Epileptic Encephalopathy; Dravet Syndrome | Nov 2026 |
| Registry id | Drug | Phase | Conditions | Area | Expected readout |
|---|---|---|---|---|---|
| NCT06719141 | LP352 | Phase 3 | Developmental and Epileptic Encephalopathy | Neurology | Nov 2026 |
| NCT06660394 | LP352 | Phase 3 | Dravet Syndrome | Neurology | Dec 2026 |
No annotated target.
–
Bigespas JYAMS PET Research & Development TriGemX Bio Zogenix ML Bio Solutions
Pipelines of the same shape: areas, drug types, target families, stage and cash runway.
Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.